Our case series reinforces the imperative for clinicians to maintain a high index of suspicion for EuDKA in diabetic patients on SGLT2is who present with unexplained metabolic acidosis, regardless of glucose levels and taking multiple drugs, including glucagon-like peptide-1 (GLP-1). This evidence concerns the gene GCG and metabolic acidosis.